Darunavir Articles
More cancer and HIV drugs added to Australian PBS
7 December 2011
Par Pharma in deal with AstraZeneca for generic Accolate; J&J unit sues Mylan and Lupin over Prezista
24 November 2010
Johnson & Johnson’s 4th-qtr/full year 2009 sales and profit exceed expectations, but forecast disappoints
27 January 2010
Johnson & Johnson’s 3rd quarter disappoints, as generics gouge leading drugs, though cost cuts help profits
14 October 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
J&J 1st qtr hit by market drop; keeps guidance
15 April 2009
J&J's 800mg Prezista launched in UK
9 March 2009
Tibotec release lower dose of Prezista
16 February 2009
J&J's Prezista gets expanded EU label
16 February 2009
J&J R&D chief calls for "open innovation"
16 February 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
J&J's Prezista non-inferior to lopinavir
1 December 2008
CHMP positive opinion for Tibotec's Prezista
1 December 2008
Janssen's mixed bag from CHMP meeting
1 December 2008
EC broadens Prezista indication
8 November 2008
Prezista achieves non-inferior virologic response to lopinavir
3 November 2008
US FDA grants J&J's Prezista expanded label
27 October 2008
Strong data for Prezista HIV regimen
1 October 2007
Combined Isentress and Fuzeon cuts HIV levels in study
12 March 2007
Aptivus resistant HIV still responds to darunavir
12 March 2007
Tibotec's Prezista cleared for HIV in EU
26 February 2007
Fuzeon plus Prezista approved for HIV in EU
26 February 2007
Correction: Tibotec's Prezista
26 February 2007
Roche welcomes advent of Fuzeon/darunavir combo
22 December 2006
CHMP recommends approval of Prezista
22 December 2006
CORRECTION: IAS HIV treatment guidelines
4 September 2006
Pricing of new AIDS drug applauded by FPC
3 July 2006
Tibotec's darunavir approved in USA
3 July 2006
Showing 1-42 of 42 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
